DK1496912T3 - Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse - Google Patents

Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse

Info

Publication number
DK1496912T3
DK1496912T3 DK03726234.2T DK03726234T DK1496912T3 DK 1496912 T3 DK1496912 T3 DK 1496912T3 DK 03726234 T DK03726234 T DK 03726234T DK 1496912 T3 DK1496912 T3 DK 1496912T3
Authority
DK
Denmark
Prior art keywords
brimonidine
timolol
combination
topical ophthalmic
ophthalmic use
Prior art date
Application number
DK03726234.2T
Other languages
English (en)
Inventor
Gary J Beck
Cynthia C Pratt
Amy L Batoosingh
Chin-Ming Chang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1496912(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1496912T3 publication Critical patent/DK1496912T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/001—Arrangement of electric circuit elements in or on lighting devices the elements being electrical wires or cables
    • F21V23/002—Arrangements of cables or conductors inside a lighting device, e.g. means for guiding along parts of the housing or in a pivoting arm
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/003—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array
    • F21V23/004—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array arranged on a substrate, e.g. a printed circuit board
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/02—Arrangement of electric circuit elements in or on lighting devices the elements being transformers, impedances or power supply units, e.g. a transformer with a rectifier
    • F21V23/023—Power supplies in a casing
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0066—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form characterised by the light source being coupled to the light guide
    • G02B6/0073—Light emitting diode [LED]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
DK03726234.2T 2002-04-19 2003-04-09 Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse DK1496912T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/126,790 US7030149B2 (en) 2002-04-19 2002-04-19 Combination of brimonidine timolol for topical ophthalmic use
PCT/US2003/010885 WO2003088973A1 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use

Publications (1)

Publication Number Publication Date
DK1496912T3 true DK1496912T3 (da) 2013-04-02

Family

ID=29215107

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03726234.2T DK1496912T3 (da) 2002-04-19 2003-04-09 Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse

Country Status (18)

Country Link
US (16) US7030149B2 (da)
EP (2) EP1496912B9 (da)
JP (1) JP2005523316A (da)
KR (1) KR100723189B1 (da)
CN (2) CN101664414A (da)
BR (1) BR0302584A (da)
CA (1) CA2440764C (da)
CY (1) CY1114048T1 (da)
DK (1) DK1496912T3 (da)
ES (1) ES2399045T3 (da)
HK (1) HK1067549A1 (da)
MX (2) MXPA03008401A (da)
NO (1) NO326579B1 (da)
NZ (1) NZ528945A (da)
PT (1) PT1496912E (da)
SI (1) SI1496912T1 (da)
TW (1) TWI351959B (da)
WO (1) WO2003088973A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US20080051406A1 (en) * 2006-08-25 2008-02-28 Richard Graham Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
MX2007010025A (es) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Composición farmacéutica para tratamiento de hipertensión ocular.
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
JP5218167B2 (ja) 2009-03-11 2013-06-26 日立電線株式会社 コネクタ
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US8317973B2 (en) 2009-11-11 2012-11-27 Kemira Chemical, Inc. Polyester surfactants for deinking
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
PE20121468A1 (es) * 2009-12-22 2012-10-28 Allergan Inc Combinacion triple para reduccion de presion intraocular
EP3434257A1 (en) 2010-07-29 2019-01-30 Allergan, Inc. Preservative free brimonidine and timolol solutions
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
BR112014014678A2 (pt) 2011-12-16 2017-06-13 Allergan Inc composições oftálmicas compreendendo copolímeros de enxertia de polivinil caprolactama-acetato de polivinila-polietileno glicol
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
EP3270892B1 (en) * 2015-03-19 2024-04-10 Allergan, Inc. Fixed dose combination of brimonidine and timolol
EP3496662A4 (en) 2016-08-12 2019-10-30 Silk Technologies Ltd. PROTEIN DERIVED FROM SILK FOR THE TREATMENT OF INFLAMMATION
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
EP3576770A1 (en) * 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
CA3066398A1 (en) * 2017-06-08 2018-12-13 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
US20200108064A1 (en) * 2017-06-08 2020-04-09 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
WO2019060846A1 (en) * 2017-09-25 2019-03-28 University Of Florida Research Foundation, Inc. ELIMINATION OF THE EYE DROPLE CONSERVATIVE CONTAINING HYDROPHILIC MEDICAMENTS
US20190134051A1 (en) * 2017-11-06 2019-05-09 Rheostasis, Llc Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
KR20200136403A (ko) * 2018-03-28 2020-12-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
US11871308B2 (en) * 2019-07-29 2024-01-09 TapText llc System and method for link-initiated dynamic-mode communications
CN115397374A (zh) 2019-12-19 2022-11-25 特清公司 从滴眼剂中去除防腐剂

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4195085A (en) * 1975-09-26 1980-03-25 Merck & Co., Inc. Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
DE4201079C3 (de) 1992-01-17 1997-09-11 Gramer Eugen Kombinationspräparate zur Augeninnendrucksenkung
US5290781A (en) * 1993-01-05 1994-03-01 Iolab Corporation Ketaneserinol as an agent to reduce intraocular pressure
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
ATE194771T1 (de) 1993-12-17 2000-08-15 Procter & Gamble 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5564596A (en) 1994-05-05 1996-10-15 Allergan, Inc. Multiple fluid dispensing device for low surface tension formulations
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
EP0861079A1 (en) 1995-11-17 1998-09-02 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
CA2322579C (en) * 1998-04-07 2001-08-28 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6146622A (en) 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
JP2004503601A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
JP2004503593A (ja) * 2000-07-14 2004-02-05 アラーガン、インコーポレイテッド 増大した溶解度を持つ治療活性成分を含む組成物
AU2001273269B2 (en) * 2000-07-14 2005-08-11 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
TWI292914B (da) * 2002-01-17 2008-01-21 Macronix Int Co Ltd
US7642258B2 (en) 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
KR100521364B1 (ko) * 2002-11-18 2005-10-12 삼성전자주식회사 플레쉬 메모리 셀들의 프로그램 오판을 방지하고 균일한문턱 전압 산포를 가질 수 있는 플레쉬 메모리 장치 및 그프로그램 검증 방법

Also Published As

Publication number Publication date
US20150087647A1 (en) 2015-03-26
CA2440764A1 (en) 2003-10-19
NO20044450L (no) 2004-11-09
US8354409B2 (en) 2013-01-15
US20210405280A1 (en) 2021-12-30
US20130196995A1 (en) 2013-08-01
CN101664414A (zh) 2010-03-10
US9474751B1 (en) 2016-10-25
EP1496912B1 (en) 2013-01-09
AU2003228480A1 (en) 2003-11-03
US7030149B2 (en) 2006-04-18
ES2399045T3 (es) 2013-03-25
US9907802B1 (en) 2018-03-06
EP1496912B9 (en) 2015-06-17
NO326579B1 (no) 2009-01-12
CN1516588A (zh) 2004-07-28
MXPA03008401A (es) 2004-03-16
US20130116255A1 (en) 2013-05-09
CN100558364C (zh) 2009-11-11
US20040102445A1 (en) 2004-05-27
US20160303119A1 (en) 2016-10-20
EP2241319A1 (en) 2010-10-20
US9770453B2 (en) 2017-09-26
KR100723189B1 (ko) 2007-05-29
US7320976B2 (en) 2008-01-22
US20130324534A1 (en) 2013-12-05
US20180042932A1 (en) 2018-02-15
KR20040100844A (ko) 2004-12-02
JP2005523316A (ja) 2005-08-04
TWI351959B (en) 2011-11-11
US20180064720A1 (en) 2018-03-08
BR0302584A (pt) 2004-03-09
TW200402296A (en) 2004-02-16
HK1067549A1 (en) 2005-06-03
US8748425B2 (en) 2014-06-10
US20030199507A1 (en) 2003-10-23
US20180064721A1 (en) 2018-03-08
PT1496912E (pt) 2013-02-13
AU2003228480B2 (en) 2006-07-27
NZ528945A (en) 2006-04-28
US20200129520A1 (en) 2020-04-30
US20030199509A1 (en) 2003-10-23
WO2003088973A1 (en) 2003-10-30
US20080132512A1 (en) 2008-06-05
US20170157138A1 (en) 2017-06-08
US7323463B2 (en) 2008-01-29
CY1114048T1 (el) 2016-07-27
CA2440764C (en) 2005-10-25
SI1496912T1 (sl) 2013-03-29
EP1496912A1 (en) 2005-01-19
US8133890B2 (en) 2012-03-13
US20120184551A1 (en) 2012-07-19
MX368377B (es) 2019-09-30
US9907801B1 (en) 2018-03-06

Similar Documents

Publication Publication Date Title
DK1496912T3 (da) Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse
NO20044137L (no) Aminoindazolderivater, deres fremstilling og anvendelse samt mellomprodukter
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DE60324099D1 (de) Arzneistoffhaltiger tampon
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DE602004028934D1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
ATE358836T1 (de) Umreifungsband
DK1603915T3 (da) Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20050689L (no) Terapeutisk anvendelse
NO20043580D0 (no) Quinazolinonderivater og deres bruk som CB agonister
NO20035224D0 (no) Oftalmisk pirenzepingel
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DE60317263D1 (de) Geradsichtprisma
DK1525193T3 (da) Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
NL1024677A1 (nl) Therapeutische prolinederivaten.
DE10391058D2 (de) Instantisierte Modifizierte Mehle
DE60322421D1 (de) Verbesserter brillenbügel
DE60236403D1 (de) Tourbillonmechanismus
DK1464341T3 (da) Ubiquinon-holdig, vandopløselig formulering til ophthalmisk anvendelse
DE50202537D1 (de) Haftklebstoff, enthaltend Vinylpyrrolidon